2018
Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J. Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabetic Medicine 2018, 35: 1096-1104. PMID: 29655290, PMCID: PMC6099360, DOI: 10.1111/dme.13629.Peer-Reviewed Original ResearchConceptsType 2 diabetesG/24 hPharmacodynamic profileType 2Type 2 diabetes trialsSodium-glucose co-transporter-2 inhibitor empagliflozinMaximum observed plasma concentrationPlasma concentration-time curveSimilar exposure-response relationshipsDoses of empagliflozinSerious adverse eventsParallel-group studyUrinary glucose excretionSingle oral doseDrug-related eventsObserved plasma concentrationConcentration-time curveExposure-response relationshipAdjusted mean increaseAdverse eventsDiabetes (ACCORD) trialGlucose excretionInhibitor empagliflozinOral doseMean age
2003
Urinary Free Cortisol Increases in Adolescent Caucasian Females during Perimenarche
Legro R, Lin H, Demers L, Lloyd T. Urinary Free Cortisol Increases in Adolescent Caucasian Females during Perimenarche. The Journal Of Clinical Endocrinology & Metabolism 2003, 88: 215-219. PMID: 12519855, DOI: 10.1210/jc.2002-020256.Peer-Reviewed Original ResearchConceptsUrinary free cortisol excretionUrinary free cortisolCortisol excretionUrinary free cortisol valuesFree cortisol excretionBody surface areaAdolescent Caucasian femaleUFC/24 hGynecological ageTanner stageG/24 hCaucasian femaleFree cortisolFemale reproductive maturationAdolescent femalesExcretionReproductive maturityPerimenarcheAge rangeLongitudinal changesPer square meterAge
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply